Page last updated: 2024-11-05

troglitazone and Kidney Diseases

troglitazone has been researched along with Kidney Diseases in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research Excerpts

ExcerptRelevanceReference
" Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules."3.73Rosiglitazone ameliorates cisplatin-induced renal injury in mice. ( Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, S1
Kim, W1
Moon, SO1
Sung, MJ1
Kim, DH1
Kang, KP1
Jang, YB1
Lee, JE1
Jang, KY1
Park, SK1
Isshiki, K1
Haneda, M1
Koya, D1
Kikkawa, R1

Reviews

1 review available for troglitazone and Kidney Diseases

ArticleYear
[Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2

    Topics: Animals; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents

2000

Other Studies

1 other study available for troglitazone and Kidney Diseases

ArticleYear
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:8

    Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinica

2006